INSIGHTS INTO FORMULATION TECHNOLOGIES AND NOVEL STRATEGIES FOR THE DESIGN OF ORALLY DISINTEGRATING DOSAGE FORMS: A COMPREHENSIVE INDUSTRIAL REVIEW by AGIBA, AHMED M. & ELDIN, AHMED B.
 
Review Article 
INSIGHTS INTO FORMULATION TECHNOLOGIES AND NOVEL STRATEGIES FOR THE DESIGN 
OF ORALLY DISINTEGRATING DOSAGE FORMS: A COMPREHENSIVE INDUSTRIAL REVIEW 
 
AHMED M. AGIBAa*, AHMED B. ELDINb 
aFormulation Department, Research and Development Directorate, SIGMA Pharmaceutical Industries, Egypt, bMethodology Department, 
Research and Development Directorate, SIGMA Pharmaceutical Industries, Egypt 
Email: ahmed.agiba@gmail.com 
Received: 09 Jul 2019, Revised and Accepted: 10 Aug 2019 
ABSTRACT 
Among the various routes of administration, the oral route remains the most convenient and commonly employed route for drug delivery. The oral 
conventional drug delivery systems have some drawbacks, such as possibility of gastrointestinal destruction of labile molecules, low absorption of 
macromolecules, slow onset of action, and unavoidable fluctuation in the concentration of drugs which can either lead to under-or over medication with 
concomitant adverse effects, especially for drugs with small therapeutic index. Therefore, it became essential to design novel oral drug delivery systems 
to achieve quick dissolution, absorption, rapid onset of action and reduction of drug dose. Among those novel drug delivery systems are oral 
disintegrating tablets (ODTs). The purpose of this review article is to report the recent advances in ODT systems with emphasis on their preparations, 
characterizations and applications. Also, it highlights future prospects and possible challenges in the development of an ideal ODT system. 
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The oral mucosal cavity is a very attractive and feasible site for local 
and systemic drug delivery, since the mucosal membranes, upon 
which drug delivery systems are placed, are readily accessible by the 
patients [1]. The oral mucosal drug delivery exhibits many 
advantages over other routs of drug administration, which include 
increased accessibility by the patients as the dosage form can be 
accurately placed on the desired oral cavity membrane location and 
can be easily removed in order to terminate delivery if signs of 
adverse reactions are observed during treatment which increases 
patient acceptability [1-3]. Moreover, the oral mucosa is a well-
vascularised tissue directly draining into the jugular vein [4], hence, 
allowing direct delivery into the systemic circulation and avoidance 
of first-pass hepatic degradation. Oral mucosal delivery also avoids 
the gastrointestinal tract (GIT) environment preventing possible 
drug hydrolysis in the GIT, in addition to avoiding enzymatic 
barriers; i.e. low gastric pH and protease enzymes. However, the oral 
mucosal drug delivery represents a challenging area because of the 
inherent functions of the oral cavity as swallowing, chewing, and 
speaking [5]. Furthermore, saliva is constantly secreted into the 
buccal cavity from both major and minor salivary glands, causing 
severe dilution of the drug or excessively fast erosion of dosage 
forms. Furthermore, salivation leads to swallowing which removes 
the drug from the targeted site of absorption. Moreover, the oral 
mucosa has a smaller absorptive surface area which is 
approximately 214 cm2 [6] compared to the gastrointestinal mucosa 
(350.000 cm2). Despite the aforementioned limitations, oral mucosal 
delivery remains a viable option for drug delivery [3]. 
There are two major routes of drug absorption via oral mucosa; the 
transcellular (where drugs permeate directly through the cells) and 
paracellular (where drugs permeate by passive diffusion through the 
spaces between the cells) routes. The drug absorption process by 
passive diffusion is best expressed by Fick’s first law [7], which 
states that drug molecules diffuse from a region of higher to lower 
concentration until equilibrium is achieved. 
 (Eq. 1) 
 (Eq. 2) 
where (P) is the permeability coefficient, (A) is the amount of drug 
absorbed via oral mucosa, (D) is the diffusion coefficient of the drug, 
(Kp) is the partition coefficient of the drug in between the oral 
mucosa and the specific medium used to deliver the drug, (h) is the 
thickness of the oral mucosa, (C) is the free drug concentration in the 
medium used to deliver the drug, (S) is the surface area of the oral 
mucosa, and (t) is the duration or time of drug interacting the oral 
mucosa. 
There must be a balance between partition coefficient and drug’s 
solubility for a suitable oral mucosal delivery. In general, the 
permeability coefficient of lipophilic drugs is higher than hydrophilic 
drugs, and vice versa for solubility (i.e. the aqueous solubility of 
lipophilic drugs are usually lower than the hydrophilic drugs). Thus, 
the amount of drug absorbed via oral mucosa may be low for high 
lipophilic drugs. As a result, permeation enhancers are subsequently 
used to enhance drug absorption and permeation [7]. 
Understanding the physicochemical and solid-state properties of a 
drug substance is essential to obtain a rational formulation process. 
The desirable physicochemical and solid-state properties for drug 
delivery through oral mucosa are shown in table 1 [3]. Two factors 
mainly affect the effectiveness of oral drug delivery systems; the 
retention time of the drug delivery system in contact with the oral 
mucosa and its permeation rate. 
The need for development of oral disintegrating tablets  
Conventional oral dosage forms like tablets and capsules pose a 
great swallowing problem for paediatrics and geriatrics. 
Approximately 35% of the general population suffers from 
dysphasia [8]. Oral disintegrating tablets (ODTs) are tablets which 
are placed in the mouth and then get dispersed in saliva without the 
need of water [9-11]. ODTs are considered the dosage form of choice 
for psychiatric patients, patients requiring fast intervention as well 
as patients suffering from nausea, vomiting and motion sickness 
[12], since the ODT system presents a patient friendly dosage form 
which ensures patient compliance and adherence to treatment. 
ODTs combine the advantages of solid and liquid dosage forms. Like 
conventional tablets, ODTs present accurate drug dosing, ease of 
both manufacturing and packaging, good chemical stability, as well 
as ease of handling by patients [13]. They also exhibit the smooth 
mouth feel and avoidance of swallowing problems encountered with 
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liquid dosage forms. Additionally, ODTs provide rapid onset of 
action and improvement of the bioavailability of poorly absorbed 
drugs [14]. An ideal ODT exhibits the following characteristics [15]: 
(1) requires no water for oral administration, (2) dissolves, 
disperses or even disintegrates in the mouth in a matter of seconds, 
(3) has a pleasant mouth feel, (4) has good taste-masking potential, 
(5) has sufficient hardness and acceptable friability limit, (6) leaves 
minimal or no residue in mouth after oral administration, (7) 
exhibits low sensitivity to environmental conditions, (8) is 
manufactured using conventional manufacturing methods, and (9) 
utilizes cost effective production method. Table 2 shows the 
suitability of drug candidates for ODTs [15]. 
 
Table 1: The desirable physicochemical and solid-state properties of a drug delivery through oral mucosa [3] 
Property Normal range 
Aqueous solubility >1 mg/ml 
Lipophilicity 10<oil: water partition coefficient<1000 
Molecular weight <500 Da 
Melting point <200 °C 
pH of saturated aqueous solution pH 5–9 
Required dose deliverable <10 mg/day 
Irritation potential No irritation to buccal tissue 
 
Table 2: Choice of drug candidates for oral disintegrating tablets [15] 
Suitable drug candidates for ODTs Unsuitable drug candidates for ODTs 
No bitter taste Short half-life and frequent dosing 
Good stability in water and saliva Drug having very bitter taste 
Taken in small doses Required controlled or sustained release 
 
The new generation of oral disintegrating tablets 
The first generation ODTs suffered from many undesirable traits, 
mainly low density, poor mechanical strength, brittleness and 
difficulty in handling. This necessitated blister packaging, which is 
not patient friendly, and causes increase in production expenses 
[16]. Another disadvantage of first generation ODTs was the 
difficulty of masking the taste of bitter active ingredients loaded 
within these tablets [17], which led to the emergence of new 
generation ODTs that overcame the problems of taste masking, 
allowed for modified release of medications, solved solubility and 
bioavailability problems, resulted in ODT tablets with excellent 
physical and mechanical robustness, mouth feel sensation, 
disintegration and dissolution properties. 
Challenges in formulating and developing oral disintegrating 
tablets 
There are several challenges in formulating and developing ODTs, 
such as: (1) palatability and acceptability [18], (2) mechanical 
strength [19], (3) the amount of drug that can be incorporated into 
an ODT system [19], (4) size of tablet [20], (5) hygroscopicity [21], 
(6) aqueous solubility [22, 23], (7) physical and chemical stability. 
Taste-masking of bitter and unpleasant taste of drugs is essential in 
order to achieve patient acceptability and compliance. Different 
techniques were developed and introduced for bitterness masking 
[24-32]. One of the most commonly used techniques for taste-
masking of bitter and unpleasant APIs or drugs is the coacervation 
process [33]. Coacervation process has successfully taste-masked a 
wide variety of bitter drugs, including but not limited to, 
acetaminophen, cetirizine, ibuprofen, pseudoephedrine, ranitidine, 
sumatriptan, theophylline and zolpidem [33]. Coupling controlled 
release behaviour with specialized functional polymers and efficient 
coating processes creates ODT systems with modified and sustained 
release profiles. 
Formulation processes for developing oral disintegrating tablets 
Various pharmaceutical techniques are used in the manufacture of 
ODTs, including: (1) freeze-drying or lyophilization [34], (2) spray-
drying [35, 36], (3) molding [37, 38], (4) phase transition process [39], 
(5) melt-granulation [40-42], (6) sublimation [43, 44] (7) mass 
extrusion [45], (8) cotton candy process [46, 47], (9) nanonization 
[48], and (10) direct compression [40, 49-53]. Admittedly, direct 
compression is the most commonly used technique in the manufacture 
of ODTs, owing to its easy-implementation and cost-effectiveness [40, 
53]. These techniques are described below in detail. 
Freeze-drying or lyophilization technique  
Freeze-drying, also known as lyophilization or cryodesiccation, is a 
technique that yields amorphous highly porous structures with 
rapid disintegration and dissolution. Orodispersible tablets made by 
lyophilization are prepared by dissolving the drug substance in an 
aqueous mixture of carrier/polymer, the solution is then poured into 
the holes of blister packs which are subsequently frozen in order to 
continue the freeze-drying cycle, followed by blistering and finally 
packaging. Lyophilization technique is very suitable for heat-
sensitive drugs (i.e. thermo-labile substances). Although ODTs 
prepared by freeze-drying process showed rapid disintegration and 
dissolution properties, but their industrial applications are limited 
since it is a high cost technique particularly in equipment and 
packing materials [34]. 
Spray-drying technique  
Spray-drying is widely used in pharmaceutical industries nowadays. 
It provides a fast, efficient and economical way of removing solvents 
and producing free flowing, highly porous particles. In this process, 
gelatin is commonly used as a supporting agent, mannitol as a 
bulking agent, and sodium starch glycolate, crosscarmellose sodium 
and/or crospovidone as superdisintegrants. Orodispersible tablets 
made by spray-drying have been reported to disintegrate and 
dissolve in less than 20 seconds [35, 36]. 
Interestingly, Allen and Wang [54] fabricated a particulate support 
matrix for preparing ODTs by spray-drying, consisting of supporting 
agents of two polypeptide components from gelatin, a bulking agent 
(mannitol) and a volatilizing agent (ethyl alcohol). In order to 
maintain the net charges of both polypeptide components, a buffer 
system of an acidifying agent (citric acid) and an alkalinizing agent 
(sodium bicarbonate) is prepared and added to the tablet mixture. 
The mixture of the aforementioned components is then spray-dried 
to obtain porous granules. By incorporating a volatilizing agent as 
ethyl alcohol, the surface tension of the droplets is further reduced, 
and more porous structures are created. An effervescent agent could 
be optionally added to further enhance the dissolution. 
Molding method 
Molding is a solid dispersion method, involving the dispersion of APIs 
in an inert water-soluble carrier or matrix at solid-state form, 
prepared by solvent or heat method. Solvent method involves 
moistening the powder mixture with alcoholic or hydroalcoholic 
solvent, then molding into tablets under reduced pressure to form wet 
paste. This process is known as compression molding. The solvent is 
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then removed from the wet paste by air-drying. The resulting tablets 
possess fine powders and highly porous structures. Solid dispersions 
are prepared directly from a molten matrix in which the drug is 
dispersed in or by vaporizing the solvent at ambient pressure (no 
vacuum lyophilization). The drug molecule can be in the form of 
discrete-particles or microparticles, completely or partially dispersed 
in the molten matrix. Because of their composition, molded tablets 
offer rapid disintegration, dissolution and improved taste, but they 
suffer the disadvantage of poor mechanical strength. Compared to 
freeze-drying, molded tablets are simpler in production and easier for 
industrial scale-up, although disintegration times may not be 
comparable to those of lyophilized forms [37, 38]. 
Phase transition process 
This process involves a combination of low-and high melting point 
sugar alcohols. Optimizing the phase transition in the manufacturing 
process is important for formulating tablets without the need of any 
equipment. Kuno et al. [39] prepared ODTs by phase transition 
process using compressible powder mixture of erythritol (a sugar 
alcohol with melting point: 122 °C) and xylitol (a sugar alcohol with 
melting point: 93-95 °C), followed by heating at 93 °C for a period of 
15 min. As a result of heating, the median pore size of tablets 
increased, as well as tablet hardness.  
Melt-granulation technique  
The melt-granulation technique is based on incorporating a 
hydrophilic melting binder in the formulation, which increases the 
physical resistance of tablets and helps their disintegration and 
dissolution. In comparison with other granulation techniques as dry-
and wet-granulation, melt-granulation is advantageous as no 
aqueous, alcoholic or even organic solvents are required. Melt-
granulation is less time-consuming, cost-effective and easy to 
perform [40-42]. 
Interestingly, Abdelbary et al. [41] described a new approach for the 
preparation of ODTs of high mechanical strength involving the use of 
a hydrophilic waxy binder, PEG-6-stearate, commercially known as 
Superpolystate® by melt-granulation. Moreover, Agiba et al. [40] 
developed high-dose nutraceutical ODTs of glucosamine sulphate 
and chondroitin sulphate using a blend of hydrophilic melting 
binders as high molecular weight polyethylene glycols (PEG-4000 
and PEG-6000). Although ODTs weighed around 1.30 gm with 60% 
drug load, they showed quick disintegration and dissolution 
properties, as well as a high mechanical strength. 
Sublimation method  
In this method, a sublimating agent like camphor is removed from 
the compressed tablets by sublimation. Highly porous structures are 
created as a result of removing camphor from the compressed 
tablets. The resulted tablets, characterized by high porous 
structures, could achieve fast disintegration in saliva. Examples of 
other volatile materials are adipic acid, ammonium carbonate, 
ammonium bicarbonate, arachidic acid, capric acid, camphor, 
menthol, myristic acid, and palmitic acid, thymol and urea. The 
sublimation temperature range is from 40 to 60 °C [43, 44]. 
Interestingly, Heinemann [55] prepared a highly porous tablet 
structure by using a mixture of volatile adjuvant, which was 
removed at the end by heating. On the other hand, Roser and Blair 
[56] removed the volatile materials by using vacuum, which reduced 
the dissolution-time from 15 min for the tablets containing trehalose 
(a disaccharide composed of 2 glucose units) alone to less than 1 
minute. Moreover, Lo [57] developed an efficient method for the 
preparation of fast-dissolving tablets with highly porous structures.  
Mass extrusion technique  
In mass extrusion, the active and inactive ingredients are first softened 
using PEGs mixture and methanol as organic solvent, followed by 
extrusion and division into tablets using heated blades [45].  
Cotton candy process  
This technique involves the formation of a matrix of poly-or 
monosaccharides using flash melting and spinning to form floss like 
crystalline structure, which is then mixed with active/inactive 
ingredients and compressed into ODTs. This process can easily 
accommodate large doses of APIs with an improved mechanical 
strength. However, high-process temperature limits its use [46, 47].  
Nanonization  
Nanomelt is a recently developed nano-based drug delivery system, 
involving a reduction of drug particle size to be in nano-scale range 
by using a proprietary wet-milling technique. APIs usually present in 
the form of nanoparticles or nanocrystals are stabilized against 
possible agglomeration by surface adsorption onto preselected 
stabilizing agents incorporated into ODT systems. This technique is 
suitable for poorly water-soluble drugs, and the produced tablets 
exhibit rapid disintegration and dissolution [48]. 
Direct compression  
Direct compression is the simplest, easiest and most widely used 
technique in ODT manufacturing, owing to its easy-implementation 
and cost-effectiveness. It involves using a blend of ingredients, which 
can provide rapid disintegration, as well as high physical integrity 
and stability. Sugar-based excipients as mannitol, sorbitol and 
lactose are commonly used as bulking agents, because of their high 
aqueous solubility and good taste-masking properties [40, 49-53].  
In general, any tablet dosage form contains one or more of 
diluents/fillers, binders/adhesives, disintegrants, 
superdisintegrants, glidant/flowing agent and lubricant. 
Disintegrants and superdisintegrants are mainly incorporated into 
tablet formulations to promote their disintegration and dissolution. 
As the ability of the tablet to rapidly disintegrate is a prerequisite in 
ODT systems, ODTs usually contain high concentrations of 
disintegrants and superdisinetgrants. Examples of disintegrants and 
superdisintegrants are listed below. 
Disintegrants and superdisintegrants 
Various disintegrants and superdisintegrants are available in the 
pharmaceutical market and are readily used for the manufacture of 
ODTs. 
Starch and modified starch 
Starch is a versatile excipient with many applications in oral solid 
dosage forms as a diluent, binder, and disintegrant. Starch acts as a 
disintegrant at a concentration of 3-25% (w/w), with an optimum 
concentration of 15% (w/w) [58-61]. However, before using starch, 
a prior granulation step is required to avoid problems associated 
with low flowability and compressibility that can cause powder 
segregation. Examples of the most commonly used starches as 
disintegrants are maize, potato, rice, tapioca and wheat starch.  
Directly compressible and modified starches have been introduced 
to overcome the problems associated with the conventional starches 
as pregelatinized starch (disintegrant) and sodium starch glycolate 
(superdisintegrant). Pregelatinized starch is a modified starch that 
has been mechanically and chemically modified through breaking all 
or part of the starch granules. Partially-pregelatinized starch, 
commercially known as Starch 1500® is a modified starch, mainly 
used in oral solid dosage forms as a diluent, binder [62, 63] and 
disintegrant [64]. Comparing conventional starches with partially-
pregelatinized starch, partially-pregelatinized starch has better 
flowability and compressibility; therefore, it may be used as a binder 
and disintegrant in direct compression. It also has self-lubricating 
property. However, when it is used with other excipients, the 
addition of a lubricant as magnesium stearate (0.25%) (w/w) is 
necessary taking into consideration that concentrations greater than 
0.25% (w/w) may have adverse effects on tablet disintegration and 
dissolution.  
Sodium starch glycolate, commercially known as Explotab® or 
Primojel®, is also used in oral solid dosage forms as a 
superdisintegrant. It is commonly used at a concentration of 2 to 8% 
(w/w), with an optimum concentration of 4% (w/w) [58]. 
Disintegration occurs by rapid uptake of water followed by rapid 
swelling [65-67]. Increasing the tablet compression pressure did not 
seem to influence the disintegration time [68, 69]. 
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Cellulose and modified cellulose 
Microcrystalline cellulose, commercially known as Avicel PH®, is 
widely used in oral solid dosage forms as a binder or diluent in both 
direct-compression, dry-and wet-granulation methods, with some 
lubricant and disintegrant properties [58]. 
Croscarmellose sodium or cross-linked carboxymethylcellulose 
sodium, commercially known as Ac-Di-Sol®, Explocel® or 
Primellose® is widely used in oral solid dosage forms as a tablet 
superdisintegrant in both direct-compression, dry-and wet-
granulations [58]. In wet-granulation, it can be added intra-and 
extragranularly, so that the wicking and swelling ability of the 
superdisintegrant is optimized [70, 71].  
Low-substituted hydroxypropyl cellulose (L-HPC) is primarily used 
as a disintegrant in both dry-and wet-granulations, also used in the 
preparation of ODTs prepared by direct compression [58]. There are 
different grades of L-HPC that have different substitution levels and 
particle sizes. For example, LH-11 has the longest fibrous particles, 
and is typically used as a disintegrant for tablets prepared by direct 
compression method, while LH-21 is less fibrous and used in case of 
tablets prepared by wet-granulation method. LH-31 is a small 
particle size grade and mainly used in extrusion process to produce 
granules. LH-B1 is non-fibrous, high-density grade, typically 
produced for fluid-bed granulation. Low substitution grades LH-22 
and LH-32 are usually used for enhancing the disintegration, and 
their concentrations are mainly depending on the characteristics of 
APIs [72]. The typical concentration of L-HPC in a solid formulation 
ranges from 5–50% (w/w) [58]. 
Crospovidone [58] 
Crospovidone or cross-linked povidone (commercially known 
Kollidon CL-M®; Polyplasdone XL®) is a tablet superdisintegrant 
used at a concentration of 2–5% (w/w) in tablets prepared by direct 
compression, dry-or wet-granulations [73]. Crospovidone can also 
be used as a solubility enhancer for increasing the solubility and 
dissolution of poorly absorbed drugs by coevaporation technique.  
Resin and its derivatives 
Ion exchange resins have been introduced as tablet disintegrants. 
The most commonly used ion exchange resin is polacrilin potassium. 
Polacrilin potassium is a highly hydrophilic cation exchange resin 
having good swelling properties [74] as well as wicking and strain 
recovery characteristics [75, 76]. It is usually used in a concentration 
of 2-10% (w/w) in tablet formulations, although 2% (w/w) was 
reported to be sufficient. 
Mechanisms of disintegrants 
Swelling 
The most common mechanism of tablet disintegration is swelling. 
Swelling is basically a dimensional-expansion process in which 
particles enlarge in every direction to push apart tablet components, 
thereby initiating the process of breaking-up of the tablet matrix [77, 
78]. The swelling property of a disintegrant depends on many 
factors including chemical structure and degree of crosslinking [79]. 
Porosity of the tablet compact plays also a significant role in 
determining the performance rate of swelling disintegrants. A tablet 
matrix with low porosity and void spaces would reduce liquid 
penetration and thereby delay or prolong the disintegration time, 
and vice versa [77]. Therefore, tablets should be prepared at an 
optimal porosity to provide adequate mechanical integrity and good 
disintegrability [80]. There is a positive correlation between the 
disintegration force development rate and the disintegration time, 
while there is no correlation between the extent of swelling of a 
disintegrant and the maximum disintegration force. Thus, the 
disintegration force development rate is essential for rapid tablet 
matrix disintegration [80] 
Wicking (capillary action) 
Wicking is a process of liquid penetration by capillary action into the 
microstructured spaces in the tablet compact to displace the 
entrapped air (i.e. through porous structures within the tablet 
compact) [77, 81, 82]. As other water-soluble ingredients rather 
than disintegrants can contribute to improving disintegration by 
increasing tablet porosity as high-molecular weight polyethylene 
glycols, so wicking cannot be classified as a primary disintegration 
mechanism. However, water penetration into the tablet compact is 
essential for disintegrant activation [79]. Thus, the penetration rate 
will mainly depend on the balance between capillary and opposite 
viscous forces [83]. 
Strain recovery (process of deformation) 
In tabletting process, tablet components are subjected to a high 
compaction pressure. During compaction, particles deform and 
interparticulate bonds are disturbed. Strain recovery is a reversible 
viscoelastic deformation process [84]. It elucidates the process of 
mechanical activation of disintegrant polymer chains when getting 
into contact with the aqueous media, causing a partial recovery into 
their original shapes [77]. Moreover, disintegration media 
contributes to the plasticization of disintegrant polymer chains and 
assists their accommodation into the most energetically stable 
positions. The resulting pressure could help in tablet disintegration 
[79]. Strain recovery process is unidirectional and exists in the 
opposite direction of exerted compaction force [78]. The recovery 
and relaxation of the stressed particles promotes rapid movement 
and volume expansion, causing the breakage of bonding bonds. 
Interruption of particle-particle bonds 
Interruption of particle-particle bonds is considered one of the most 
important mechanisms for tablet disintegration. Some previous 
studies suggested three different possible bonding mechanisms 
involved in tableting which are solid bridges, mechanical 
interlocking, and intermolecular forces [85]. Among those three 
bonding mechanisms, intermolecular forces are considered the most 
prevalent bonding mechanism in tablet disintegration [85, 86]. 
Various techniques have been introduced to identify the 
intermolecular bonds involved in the interruption of the tablet 
matrix. Luangtana-Anan et al. [87] showed a correlation between the 
intermolecular forces present in tablets and the disintegration time.  
Heat of interaction 
Two types of interactions result from the interaction of materials 
with aqueous media; endothermic (heat absorption) and exothermic 
(heat generation) [77]. Exothermic interactions are obtained from 
interacting disintegrants with the aqueous media, either water or 
buffer compartment [88], hence the heat generated causes localized 
stress within tablets which is usually associated with an expansion 
of air retained in the tablet compact, and subsequently increased 
disintegration time. Lowenthal [87] illustrated the importance of 
heat generation as an important mechanism in tablet disintegration. 
However, Luangtana-Anan et al. [88] explained the changes in 
enthalpy for different disintegrants and concluded that the amount 
of heat generated by wetting is rather small and insufficient to cause 
effective expansion of the entrapped air in the tablet compact. 
Furthermore, Caramella et al. [89] studied the relation between the 
temperature of the disintegration media and disintegration time and 
concluded that increasing the temperature of the aqueous media did 
not necessarily improve the disintegration process. Therefore, it is 
necessary to further study the mechanism of heat of interactions to 
identify its impact on tablet disintegration. 
Coprocessed and multifunctional excipients 
Developing a robust tablet formulation that can be easily scaled up 
to a drug product without any problematic issues is a big challenge. 
Today, there are many challenges in product manufacturing and 
scaling up; therefore, the need of new pharmaceutical techniques 
and novel excipients are necessary for manufacturing a high-quality 
product. Coprocessed and multifunctional excipients are designed to 
improve the formulation experience and performance. They are 
high-functionality excipients containing one or more diluents, 
binders, disintegrants, superdisintegrants and/or lubricants that 
could provide superior binding, high mechanical strength, quick 
disintegration and dissolution. The basic principle of coprocessing is 
based on particle engineering technologies. Any powdered 
substance is characterized by three different levels of solid-state; 
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molecular level (individual molecule level), particle level (individual 
solid particle level) and bulk level (as assembly of particulate 
species) [90]. These different levels are closely connected to each 
other in which changing in one level affects the other levels. The 
molecular level involves the arrangement of individual molecules in 
the crystal lattice and represented by polymorphism, pseudo-
polymorphism, and the amorphous state. Particle level involves 
individual solid particle properties like arrangement, shape, size, 
surface area, and porosity. The bulk level involves large numbers of 
particles together and their properties like flowability and 
compressibility. All these levels are essential for evaluating the 
performance of excipients. 
Methods of coprocessing include spray-drying, granulation, 
extrusion/spheronization, melt-extrusion, solvent-evaporation and 
crystallization. Examples of commonly used coprocessed and 
multifunctional excipients are listed in table 3. Coprocessed and 
multifunctional excipients represent the ultimate solution in 
developing orodispersible tablets with very few excipients and high 
functionalities and physicomechanical properties. 
 
Table 3: The most common examples of high-functionality excipients 
Excipient Composition Manufacturer 
Prosolv® SMCC Silicifed Microcrystalline Cellulose JRS Pharma 
Prosolv® EASYtab SP Microcrystalline Cellulose 
Colloidal Silicon Dioxide 
Sodium Starch Glycolate  
Sodium Stearyl Fumarate 
JRS Pharma 





Prosolv® EASYtab Nutra GM Microcrystalline Cellulose 
Silicon Dioxide 
Sodium Starch Glycolate 
Magnesium Stearate 
JRS Pharma 
Prosolv® EASYtab Nutra CP Microcrystalline Cellulose 
Silicon Dioxide 
Croscarmellose Sodium 
Sodium Stearyl Fumarate 
JRS Pharma 






Mannogem® EZ Spray-dried Mannitol SPI Pharma 
Mannogem® XL Spray-dried Mannitol SPI Pharma 
Compressol® SM Mannitol, Sorbitol SPI Pharma 
Advantose® 100 Spray-dried Maltose SPI Pharma 
Advantose® FS95 Spray-dried Fructose SPI Pharma 
Lubripharm® SSF Sodium Stearyl Fumarate SPI Pharma 
Pharmaburst® C1 Mannitol 
Sorbitol 
Crosspovidone 
Colloidal silicone dioxide 
SPI Pharma 
Tabulose® Colloidal Microcrystalline Cellulose Roquette Pharma 
Pearlitol® Spray-dried Mannitol Roquette Pharma 
Pearlitol® Flash Mannitol, Starch Roquette Pharma 
Starlac® Starch, Lactose Roquette Pharma 










Soluplus® Polyethylene glycol 
polyvinyl acetate  
Polyvinylcaprolactame 
BASF Pharma 
Sepitrap™ 80 Magnesium Aluminometasilicate 
Polysorbate 80 
SEPPIC 
Sepitrab™ 4000 Magnesium Aluminometasilicate 
Polyoxyl 40 Hydrogenated Castor Oil 
SEPPIC 
HiCel™ HFE Microcrystalline Cellulose, Mannitol Sigachi Industries Pvt. Ltd 
HiCel™ CE15 Microcrystalline Cellulose,  Guar gum Sigachi Industries Pvt. Ltd 
HiCel™ SMCC Microcrystalline Cellulose 
Colloidal Silicon dioxide 
Sigachi Industries Pvt. Ltd 
HiCellac™ 80 and 100 Microcrystalline Cellulose 
Lactose Monohydrate 
Sigachi Industries Pvt. Ltd 
HiCel™ DG Microcrystalline Cellulose  
Dicalcium phosphate 
Sigachi Industries Pvt. Ltd 
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Several patented technologies are introduced for the manufacture 
of ODTs [14, 25, 53], including: (1) Zydis® technology [22], (2) 
Lyoc® technology [92], (3) WowTab® technology [93, 94], (4) 
FlashTab® technology and Multiflash® [49], (5) Durasolv® and 
Orasolv® technologies [95, 96], (6) Frosta® technology [14], (7) 
AdvaTab® technology [97], (8) FlashDose® technology [98], (9) 
OraQuick® technology [14], (10) Nanocrystal® and EFVDAS® and 
FastMelt® technologies [14, 99], (11) QuickDis® technology, and 
(12) Pharmabrust™ technology [14]. Table 4 summarizes the 
patented techniques used for the manufacture of ODTs and table 5 
shows examples of globally marketed oral disintegrating tablets 
products.
  
Table 4: Patented technologies used to produce ODTs 
Technology Company Description Novelty aspect Advantages Disadvantages 
Zydis® [22] R. P. Scherer 
Corporation 
- Lyophilizing the drug in a water-soluble 
matrix usually consisting of mannitol (a 
crystalline sugar) and gelatin (a water-
soluble polymer). 
- Other excipients can be used depending on 











- Expensive manufacturing 
process 
- Require special packaging 
materials  
- Unstable at higher 
temperature and humidity 
- Incompatible with high 
drug doses 
Lyoc® [92] Cephalon 
Corporation 
- A freeze drying process but differ from 
Zydis where the drug product is frozen on 
freeze dryer shelves. 
- The homogeneous liquid or suspension is 
placed into blister cavities and subjected to 
freeze drying. 
- The homogenous liquid or suspension 
contains one or more of water-soluble fillers, 
thickening agents, surfactants and the drug 
substance. 
 A modified 
form of Zydis 
- Self-
preservative 
- Expensive manufacturing 
process 
- Require high amounts of 
fillers to prevent possible 
sedimentation 
- The high amounts of fillers 
can reduce tablet porosity 
and prolong disintegration 








- Wow means without water 
- This process involves granulating low-
moldable sugars (e. g. mannitol, lactose, 
sucrose and glucose) that show rapid 
dissolution with high-moldable sugars (e. g. 















- This process involves coating a drug with a 
polymer as Eudragit to provide a rapid drug 
release in the stomach and formulating this 
microencapsulated drug with an effervescent 
base to produce a flash dispersible tablet.  
- This technology comprises the granulation 
of a drug and excipients by either dry-or wet-






















- Conventional tabletting process (i.e. a 
direct compression method using higher 









- strength than 
Orasolv 
- Good tablet 
rigidity 
- Easy to 
perform 
- Low cost 
- Packaged in 
blisters, foil or 
bottles 
- Incompatible with high 
drug doses because the 
formulations are subjected 
to high compaction 
pressures. Unlike OraSolv, 
the structural integrity of 
any taste-masking may be 
compromised with high drug 
doses. 




- Conventional tabletting process (i.e. direct 
compression method using an effervescent 
base and taste masked drug.) 
- Effervescence agents cause the tablet to 
disintegrate rapidly in less than 1 min once 
contact with water or saliva, leaving coated 
drug powder. 
- Effervescent agents include carbonates such 
as sodium bicarbonate, sodium carbonate, 
potassium bicarbonate and potassium 
carbonate, magnesium carbonate, and acids 









- Low mechanical strength 
- Soft and fragile 
- Tablets; therefore, a 
special packing material 
system is required 




Akina - This technique comprises formulating 
plastic granules and compressing them at low 
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- Plastic granules may contain porous and 
plastic materials, penetration enhancers and 
binders 
- The manufacturing process includes mixing 
the porous plastic materials with penetration 
enhancers, followed by granulating with the 




Eurand - A microencapsulation process for coating 
the drug particles with gastro soluble 
polymer to mask the bitter taste along and 
prevent the drug dissolution in mouth cavity. 
- It can be combined with Eurand’s 
complimentary particle technologies as 
Microcaps® (taste-masking technology) and 















- This technique comprises a unique spinning 
mechanism to produce a floss-like crystalline 
structure, much like cotton candy process. 
- This crystalline sugar-based matrix (floss) 
can incorporate the active drug and be 
compressed into tablets.  
- Instead of a floss-like crystalline sugar, 
small spheres of saccharides can be used as a 









- High surface 
area for drug 
dissolution 
- Require special packing 
materials as tablets are 
highly friable. 
- Require high temperature  
to melt the matrix; therefore, 
it cannot be used with heat 
and moisture sensitive drugs 
- It is suitable for doses up 





ical Co., Inc. 
- Taste masking process is done by 
incorporating drug into matrix microsphere. 
- In this technique, tablets are prepared by 
dissolving the sugar (e. g. mannitol, sorbitol 
or sucrose) and protein (gelatin or albumin) 
in a aqueous, alcoholic or hydroalcoholic 
solvent. The matrix is then spray dried, 
yielding highly porous granules.  
- The formed granules are mixed with the 
drug and other excipients then compressed 













al ® [14] 
Elan 
Corporation 
- The main concept of this technology is 
decreasing drug particle size and increasing 
surface area for drug absorption.  
- Nanocrystal particles are small particles of 
the drug substance, typically less than 1000 
nm in diameter, which are 
- Manufactured by milling the drug substance 
using a suitable wet-milling method. 
- Nanocrystal colloidal dispersions of drug 
substances have been combined with water-
soluble ingredients as mannitol and sorbitol, 
filled into blisters, and freeze-dried. The 
resultant blisters are remarkably robust yet 
dissolve in very small quantities of water in 
matter of seconds. This approach is suitable 
with highly potent or hazardous materials. 
Wet-milling 
technique 









- suitable for 
doses up to 200 





- Known as Effervescent Drug Absorption 
System (EFVDAS) 
- Examples of EFVDAS products are 
















- Combine the advantages of liquid 
formulations with those of solid dosage 
forms 
- Characterized by highly porous, micro-fine 
matrix tablet 
- Once placed onto the oral cavity, the 
matrix tablet rapidly absorbs water and 
disintegrates, and the drug is released into 







SPI Pharm - Tablets are manufactured by direct 
compression of drug substances, 
pharmabrust, flavours, colorants and a 
lubricant. 
- Tablets dissolve within 30-40 seconds. 
- Tablets have sufficient strength and can be 
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Table 5: A list of marketed orally disintegrating tablet products 
Commercial product Active ingredient Indication Manufacturer Technology 
Abilify® Aripiprazole Anti-psychotic Otsuka America 
Pharmaceutical, Inc. 
Zydis® 
Children’s Dimetapp® ND Loratadine Anti-histaminic Wyeth Consumer Healthcare 
Claritin® RediTabs® Loratadine Anti-histaminic Bayern Schering Corporation 
Feldene Melt™ Piroxicam Anti-inflammatory Pfizer 
Grastek® Sublingual Tablets Pollen allergen extract from 
Timothy grass (Phleum 
pratense) 
Timothy grass or related 
grass-pollen allergies 
Catalent Pharma Solutions 
for ALK-Abelló A/S 
Grazax 75,000 SQ-T Oral 
Lyophilisate 
Pollen allergen extract from 
Timothy grass (Phleum 
pratense) 





Imodium® Quick Dissolve 
Loperamide HCl Anti-diarrheal Johnson and Johnson 
Klonopin® Wafers Clonazepam Anti-convulsive and 
Anxiolytic 
Roche 
Maxalt-MLT® Rizatritpan benzoate Anti-migraine Merck 
Motilium® Domperidone Anti-emetic Johnson and Johnson 
Ondansetron-RL Zydis® Wafers Ondansetron HCl Anti-emetic GlaxoSmithKline 
Ondaz Zydis® Wafers Ondansetron HCl Anti-emetic Sandoz 
Pepcid® Famotidine Anti-ulcer Merck 
Ragwitek® Sublingual Tablets Pollen allergen extract from 
Short Ragweed (Ambrosia 
artemisiifolia) 
Ragweed pollen allergies ALK-Abelló A/S 
Risperdal® M-Tab™ Risperidone Anti-psychotic Johnson and Johnson 
Zelapar™ Selegiline HCl Parkinson’s disease Elan/Amarin Corporation 
Zofran® ODT Ondansetron HCl Anti-emetic GlaxoSmithKline 
Zubrin® Tepoxalin Anti-inflammatory Schering Corporation 
Zyprexa® Olanzapine Anti-psychotic Eli Lilly 
Loperamide® Lyoc® Loperamide chlorhydrate Anti-diarrheal Teva Lyco® 
Paralyoc® Paracetamol Analgesic, anti-pyretic Teva 
Proxalyoc® Piroxicam  Anti-inflammatory Teva 
Seglor® Lyoc® Dihydroergotamine mesylate Migraine UCB Pharma 
Sermion® Lyco® Nicergoline Potent vasodilator Pfizer 
Spasponlyoc® Phloroglucinol dihydrate Anti-spasmodic Teva 
Vogalene® Lyoc® Metopimazine  Anti-emetic Teva 
Reminly® OD Tablets Galantamine Alzheimer's disease Janssen/Takeda Quicksolv® 
Risperdal® M-Tab Risperidone Anti-psychotic Janssen Pharma 
Allegra® Fexofenadine  Anti-histaminic Aventis Pharmaceuticals OraSolv® 
Clarinex RediTab® Desloratadine Anti-histaminic Schering-Plough 
Fluxid™ Famotidine  Anti-ulcer Azur Pharma 
Orapred® ODT Prednisolone sodium phosphate Asthma Concordia Pharmaceuticals 
Remeron® SolTab  Mirtazapine Anti-depressant Organon Inc. 
Tempra® Quicklets/ 
Tempra® FirsTabs 
Acetaminophen Analgesic Bristol-Myers Squibb 





Cold cough Novartis Consumer Health 
Zomig® Rapimelt Zolmitriptan Migraine  AstraZeneca 
Alavert® Loratadine Anti-histaminic Wyeth Consumer Healthcare DuraSolv® 
Dimetapp® ND Loratadine Anti-histaminic Wyeth Consumer Healthcare 
FazaClo® LD (low dose) 
and FazaClo® HD (high dose) 
Clozapine Schizophrenia  Alamo Pharmaceuticals 
Kemstro™ Baclofen Anti-spastic analgesic Schwarz Pharma 
Niravam™ Alprazolam Anxiety Schwarz Pharma 
NuLev®  Hyoscyamine sulfate Antispasmodic  Schwarz Pharma 
Benadryl® Fastmelt Diphenhydramine Citrate Anti-histaminic Pfizer WowTab® 
Gaster® D  Famotidine Anti-ulcer Yamanouchi 
Harnal® D Tamsulosin HCl Benign prostatic 
hyperplasia 
Astellas Pharma Inc. 
Irribow® OD Ramosetron HCl Irritable bowel syndrome Astellas Pharma Inc. 
Nasea® OD  Ramosetoron HCl Anti-emetic Yamanouchi 
Vesicare® OD Solifenacin succinate Overactive bladder Astellas Pharma Inc. 
Calpol® Six Plus Fastmelts Paracetamol Analgesic, anti-pyretic McNeil Products Ltd Flashtab® 
Dolflash® Acetaminophen Analgesic, anti-pyretic Sanofi-Aventis 
Excedrin Quicktabs Acetaminophen, Caffeine Analgesic, anti-pyretic Bristol-Myers Squibb 
Nurofen® Flashtab Ibuprofen Analgesic, anti-pyretic Boots Healthcare 
Ondansetron Flashtab®  Ondansetron Anti-emetic Teva 
OxynormOro®  Oxycodone chlorhydrate Cancer related pain Mundipharma 
Paracetamol Flashtab® Paracetamol Analgesic, anti-pyretic Ranbaxy 
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(Delayed release ODT) 
Lansoprazole Gastroesophageal reflux 
disease 
Takeda 
Solupred Orodispersible Tablet Prednisolone Asthma Sanofi-Aventis 
Tachipirina Flashtab® Paracetamol Analgesic, anti-pyretic Angelini 
Tramalene® Flashtab® Tramadol HCl Potent analgesic Ethypharm 
Trambax® MD Tramadol HCl Potent analgesic Ranbaxy 
Zamadol® Melt Tramadol HCl Potent analgesic MEDA Pharma 
Citalopram® ODT Citalopram hydrobromide Anti-depressant Biovail FlashDose® 
Fluoxetine® ODT  Fluoxetine Anti-depressant Biovail 
Ralivia FlashDose®  Tramadol HCl Potent analgesic Biovail 
Tovalt™ ODT  Zolpidem tartrate Insomnia Biovail 
Lamictal® ODT Lamotrigine Bipolar disorders GlaxoSmithKline AdvaTab® 
Unisom® SleepMelt Diphenhydramine HCl Anti-histaminic Chattem, Inc. 
Caffe Magia® Vitamin B and Caffeine Stimulant Akina Frosta® 
Ceto-Q® Mannitol, Calcium carbonate, 
Xylitol, Yucca extract 
Toothpaste tablet Akina 
Hyoscyamine Sulfate ODT  Hyoscyamine sulfate Anti-ulcer Perrigo OraQuick® 
 
Characterizations of oral disintegrating tablets 
Evaluation of powders or granules (pre-compression 
parameters evaluation) 
Bulk and tapped density  
Ten gm of a dry powder or granular sample is placed in a 100 ml 
graduated cylinder. The volume occupied by the powder or granules 
is measured and the bulk density is calculated using equation 3. 
Tapped density is determined by a tapped density tester. The 
volume occupied by the powder or granules after tapping is used to 
calculate the tapped density using equation 4 [40, 100]. 
 (Eq.3) 
 (Eq. 4) 
Hausner ratio and carr's compressibility index 
Hausner ratio and carr's compressibility index are calculated based 
on bulk and tapped density results using equations 5 and 6, 
respectively. 
 (Eq. 5) 
 (Eq. 6) 
Flowability is determined based on the results of hausner ratio and 
carr's compressibility index as shown in table 6. 
  
Table 6: Specification for hausner ratio and carr's compressibility index 
Hausner ratio Carr's compressibility index (%) Flowability 
1.00-1.11 0-10 Excellent 
1.12-1.18 11-15 Good 
1.19-1.25 16-20 Fair 
1.26-1.34 21-25 Passable 
1.35-1.45 26-31 Poor 
1.46-1.59 32-37 Very poor 
>1.60 >38 Very, very poor 
 
Table 7: Specification of angle of repose (Ɵ) 






56-65 Very poor 
>66 Excellent 
 
Angle of repose (Ɵ)  
Angle of repose (Ɵ) is determined by the fixed funnel and free-
standing cone method. The method employed a funnel that is fixed at 
a certain height (h) on a graph paper placed on a flat horizontal 
surface. The powder or granules sample is carefully passed through 
the funnel till the apex at the conical pile touched the tip of the 
funnel. Thus, with (r) being the radius of the base of the conical pile 
as shown in equation 7 [101]. 
 (Eq. 7) 
Where, (h) and (r) are the height and radius of the base of the 
conical pile 
Flowability is determined based on the results of angle of repose as 
shown in table 7. 
Porosity (ε)  
Porosity (ε) is calculated from apparent density (ρapp) and true 
density (ρtrue) as in equation 8 [40]. 
 (Eq. 8) 
The true density (ρtrue), which is the density of the particles that 
make up a powder or particulate solid, is measured by gas 
displacement using a pycnometer [102]. 
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Evaluation of tablets (post-compression parameters 
evaluation) 
(1) Weight uniformity or % of weight variation  
Twenty tablets were randomly selected from the production batch 
and weighted individually to check their weight uniformity. The 
percentage of weight variation is calculated using equation 9 [40, 
103]. 
 (Eq. 9) 
The percentage of tablet weight deviation is shown in table 8. 
 
Table 8: Uniformity of weight of tablets 
Average tablet weight (mg) % Deviation 
Less than 80 mg ±10 
More than 80 mg but less than 250 mg ±7.5 
250 mg and more ±5 
 
Tablet hardness  
Tablet hardness is measured by the hardness tester in newton (N) or 
kilopond (kP) per unit tablet. Each tablet is placed individually in the 
hardness tester and the crushing load is measured. In general, the 
hardness of ODTs is set to be lower than conventional tablets 
because of increasing hardness results in decreasing tablet 
disintegration rate [40, 103]. 
Tablet friability  
Twenty tablets are accurately weighted and placed in the friabilator 
chamber, then allowed to rotate at 25 rpm for 4 min. Tablets are 
collected and reweighted. The percentage of weight loss in tablet is 
calculated using equation 10 and taken as a measure of friability. 
Tablets pass the friability test if not more than 1% of the tablets 
weight was lost [40, 103].  
 
W0: initial weight of tablets 
Wf: final weight of tablets 
Tablet thickness and diameter  
Tablet thickness and diameter are measured by using a micrometer 
caliper in millimeter (mm) per unit tablet [40]. 
Uniformity of dispersion  
Twenty tablets are placed in a beaker containing 100 ml of purified 
water and stirred gently for 2 min. The dispersion is allowed to pass 
through 22 mesh screen. Tablets would pass the test if no residue 
remained on the screen [104]. 
Water absorption ratio  
A small piece of tissue paper folded twice is placed in a small 
petridish containing 6 ml of purified water. A tablet is placed onto 
the tissue paper and the time required for completely wetted is 
measured. The wetted tablet is then re-weighed. Water absorption 
ratio (R) is calculated by using equation 11 [104]. 
 (Eq. 11) 
Wb: is the weight of tablet before water absorption 
Wa: is the weight of tablet after water absorption 
Wetting time  
Five circular tissue papers of 10 cm diameter are placed in a 
petridish with a 10 cm diameter. Ten millimeters of water 
containing Eosin, a water-soluble dye, is added to petridish. A tablet 
is carefully placed on the surface of the tissue paper. The time 
required for water to reach upper surface of the tablet is noted as a 
wetting time [50, 101]. 
In-vitro disintegration time  
Disintegration time is evaluated using the disintegration tester 
without disk. The disintegration medium is usually 900 ml of 
purified water kept at 37±0.5 °C. The time required for complete 
disintegration is in seconds [40, 103]. 
In-vitro and comparative dissolution  
Four dissolution medias are commonly used for evaluating in vitro 
and comparative dissolution, namely 0.1N HCl (pH 1.2), acetate 
buffer (pH 4.5), phosphate buffer (pH 6.8) and artificial saliva 
solution (pH 7.0). Dissolution tester is used for experimental 
evaluation following the USP paddle (most common). All dissolution 
tests are usually conducted in 900 ml of each dissolution media 
maintained at a constant temperature of 37 °C±0.5 °C with paddle 
rotation speed of 25, 50, 75 or 100 rpm. Comparative dissolution 
studies is mainly conducted against the reference marketed product. 
Dissolution profiles are compared with the reference marketed 
product using the similarity factor (f2) defined by the following 
equation 12 [40, 103]. 
 (Eq. 12) 
Where (n) is the number of sampling time points, (Rt) and (Tt) are 
the mean percent dissolved of the reference product and the 
prepared ODTs respectively, up to each time point (t), (f2) represents 
a logarithmic transformation of the sum-squared error of difference 
between the reference and the test products over all time points. In 
order to consider similar dissolution profiles, (f2) values should be 
higher than 50. 
Novel formulations of oral disintegrating tablets 
Many reported applications of ODTs have been described in the 
literature. Agiba et al. [40] incorporated a high dose of 
nutraceuticals glucosamine sulphate (GluS) and chondroitin 
sulphate (CS) into ODTs in order to improve their disintegration, 
dissolution and subsequent their bioavailability. GluS/CS ODTs were 
prepared by direct compression and melt-granulation techniques, 
using a blend of conventional and coprocessed multifunctional 
excipients as Pharmaburst™ C1. Pharmaburst™ C1 turned out to be 
the key excipient in improving the tablet characteristics, 
disintegration and dissolution profile. Kumar and Saharan [101] 
developed ODTs of salbutamol sulphate, using a combination of 
three different superdisinetgrants in different ratios. They 
concluded that the binary combination of superdisintegrants was 
more effective in disintegration and dissolution than the individual 
use of one superdisintegrant. Dave et al. [105] developed ODTs of 
chlorpheniramine maleate based on lyophilization technique, using 
superdisinetgrants as croscarmellose sodium and crospovidone for 
faster disintegration and dissolution. Türkmen et al. [106] developed 
fexofenadine hydrochloride ODTs by direct compression using high 
functionality excipients as F-Melt®, Pearlitol® Flash, Pharmaburst® 
500, Prosolv® Easytab SP, Ludiflash® and Parteck® ODT. ODTs 
formulated with Pharmaburst® 500 were the most promising 
formulation with respect to physical characteristics and dissolution 
rate. Shoormeij et al. [107] developed meloxicam ODTs using solid 
dispersions followed by direct compression. Meloxicam solid 
dispersions were prepared by the melting method, using poloxamer 
188 as a hydrophilic carrier and crospovidone as a 
superdisintegrant. Moqbel et al. [108] developed ODTs of 
Agiba et al. 
Int J Pharm Pharm Sci, Vol 11, Issue 9, 8-20 
 
18 
chlorzoxazone using two different approaches; co-processed 
excipients or liquisolid technique. F-melt®, Pearlitol® flash, 
Pharmaburst® 500, Prosolv® ODT and Starlac® were used as co-
processed multifunctional excipients, whereas in liquisolid method, 
Avicel® PH101, Cellactose® 80 and Microcelac® 100 were used as 
carriers, while Aerosil® 200 was a coating material. Both approaches 
were capable of producing ODTs with ease and low cost of 
manufacture. ODTs formulated with Pharmaburst® 500 showed the 
best results in terms of palatability, mechanical strength, 
disintegration and dissolution. Ibrahim and El Sayeh [109] 
formulated orally disintegrating tablets containing furosemide; a 
potent diuretic used mainly in the management of hypertension. 
ODTs were prepared by direct compression method for taste-
masking purposes. Nishiyama et al. [110] prepared taste-masking 
granules of lafutidine for ODTs using water-insoluble/water-soluble 
polymers combinations. Lafutidine taste-masking granules were 
prepared by coating lafutidine granules with a taste-masking layer 
prepared by combining ethylcellulose (water-insoluble polymer) 
and hypromellose (water-soluble polymer), and ODTs were 
prepared by direct compression method using mannitol as a diluent, 
low-substituted hydroxypropyl cellulose as a disintegrant and 
sodium stearyl fumarate as a water-soluble lubricant. Desai et al. 
[111] developed β-cyclodextrin (β-CD) solid dispersion-based ODTs 
of eslicarbazepine acetate (ESL), for improving the dissolution and 
providing rapid anti-epileptic action. ESL-β-CD solid dispersion was 
prepared by solvent evaporation method and then compressed into 
ODTs by direct compression, using superdisintegrants as 
crosspovidone, sodium starch glycolate, pregelatinzed starch and 
croscarmellose. Microcrystalline cellulose was further added to aid 
in tabletting. Yıldız et al. [112] developed new ODTs containing 
mirtazapine; an antidepressant drug molecule having bitter taste by 
coacervation followed by direct compression using different fillers 
(Ludiflash®, Phamaburst™ C1, Galen® IQ, F-Melt® and Mannitol 
Parteck® M100), disintegrants (Kollidon® CL, Ac-Di-Sol®, Explotab® 
and Kollidon® CL/Amberlit® IRP-88 mixture), glidant (Aerosil® 200), 
citric acid and sodium carbonate (effervescent mixture). Chen et al. 
[113] prepared montelukast sodium ODTs with a similar dissolution 
profile as the marketed product, Romilast® ODTs (Ranbaxy). 
Montelukast sodium ODTs were prepared by direct compression 
and wet-granulation methods, using a variety of excipients such as 
microcrystalline cellulose (M105 and M301), mannitol (SD200 and 
160C), croscarmellose soldium, hydroxypropyl cellulose, and 
magnesium stearate. The prepared ODTs showed equivalent 
dissolution profiles to the marketed product in four different media. 
El-Maghraby and El-Sergany [114] enhanced the intra-oral 
administration of nisoldipine used in the treatment of angina 
pectoris and hypertension by its formulation in ODTs with 
subsequent fast dissolution. Nisoldipine ODTs were formulated by 
solid dispersion technique by using solvent evaporation method. 
Cantor et al. [115] described a novel formulation approach for taste-
masking drugs with poor organoleptic properties such as 
clindamycin hydrochloride. Taste-masked ODTs of clindamycin 
hydrochloride were prepared by its coating with microcrystalline 
cellulose beads followed by the addition of a taste-masking layer of 
amino methacrylate copolymer coating suspension. 
Future prospects and possible challenges in the development of 
oral disintegrating tablets  
Despite the advances in ODT technologies, formulation of 
hydrophobic drugs with poor bioavailability is still a big challenge, 
particularly at high doses. The need of a new technology to 
incorporate higher doses of hydrophobic drugs without affecting the 
mechanical and disintegrating properties is crucial. The 
disintegration times of most marketed ODTs are acceptable (within 
3 min as stated by European Pharmacopeia), but certainly further 
improvement would be an advantage. Generally, the disintegration 
time is affected by many formulation variables, therefore, a balance 
between the disintegration time and other tablet properties as 
mechanical strength, friability, thickness and diameter should be 
well-considered. Development of cheap and effective direct taste-
masking methods would also be advantageous. On the other hand, 
the development of ODTs usually requires large amounts of 
excipients and having large drug doses will make the final dosage 
form very large. Therefore, the formulation of ODTs containing high 
doses drugs is still a problematic issue and need further new and 
advanced technologies. 
CONCLUSION 
The popularity of ODTs has increased dramatically over the last few 
decades. There are many globally marketed products that have been 
formulated into ODT dosage forms. The most important parameters 
in ODT formulations are rapid onset of action, very fast drug release, 
quick disintegration and dissolution, and these could be achieved by 
formulating tablets with high porous structures or by adding a blend 
of disintegrants, superdisintegrants, effervescent systems, and/or 
coprocessed multifunctional excipients. ODTs prepared by direct 
compression technique usually have good mechanical properties but 
could be further improved by using high functionality excipients. 
Considering many advantages and benefits of ODT systems, it is only 
a matter of time till the majority of oral solid dosage forms become 
ODT formulations. 
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